Core Insights - Prenetics Global Limited will release its financial results for Q4 and full year 2025 on February 18, 2026, before market open [1] - An earnings conference call will be held on the same day at 10:00 a.m. Eastern Time, including a Q&A session with analysts [1][2] Company Overview - Prenetics is a leading health sciences company focused on advancing human health and longevity, with its flagship brand IM8 co-founded by David Beckham [3] - IM8 has rapidly grown, surpassing $100 million in annualized revenue within 11 months and is now available in over 30 countries [3] - IM8's flagship product, Daily Ultimate Essentials, is designed to replace 16 different supplements and is NSF Certified for Sport, non-GMO, vegan, and free from common allergens [4]

Core Insights - Prenetics Global Limited has completed the sale of its 3PL distribution business, Europa Sports Partners, valued at up to $13 million, to focus on its IM8 brand [1][2][3] - The company maintains a strong balance sheet with over $70 million in cash and cash equivalents, 510 BTC, and zero debt, totaling approximately $118 million in liquidity [1][3] - The divestiture is part of Prenetics' strategic portfolio optimization, following the $72 million sale of ACT Genomics in October 2025, aimed at concentrating resources on the high-growth IM8 business [3][5] Financial Performance - The sale of the Europa business, completed on January 1, 2026, will not impact the company's revenue for fiscal year 2025, which will include the full-year contribution from Europa [4] - Prenetics projects total revenues from IM8 to be between $180 million and $200 million for the full year 2026 [3] - The divestiture is expected to improve operating margins starting Q2 2026, as the company will no longer incur approximately $6 million in operating losses from the Europa business [6] Strategic Focus - The sale allows Prenetics to sharpen its focus on IM8, which is rapidly scaling across international markets, aligning with the company's long-term logistics and global expansion requirements [2][5] - Prenetics plans to continue reviewing its remaining non-core assets, including a 35% stake in Insighta, valued at $70 million, to further simplify its business structure [7] - The company is optimistic about the future opportunities for IM8, which has achieved over $100 million in annual recurring revenue within 11 months of launch [8]

Core Insights - Prenetics Global Limited reported a significant increase in total revenue, surging 568% year-over-year to $23.6 million in Q3 2025, with a gross profit of $14.0 million, reflecting a 631.2% increase compared to Q3 2024 [14][25][9] - The company's IM8 brand achieved record monthly revenue of $9 million in October 2025, marking a 36% month-over-month growth from September [4][2] - IM8 is projected to reach $180 to $200 million in revenue for FY 2026, translating to approximately $25 million in monthly revenue or $300 million in annual recurring revenue (ARR) by the end of 2026 [21][11] Financial Performance - Q3 2025 financial highlights include a quarterly revenue of $23.6 million, a gross margin of 60%, and an adjusted EBITDA loss of $(2.1) million, improving from $(4.5) million in Q1 2025 [14][9][10] - The company reported a total of 420,000 customer purchases across 31 countries, with international markets contributing 56.5% of IM8's revenue [5][4] - The average order value for new customers increased to $150 in October 2025, up 36% from the previous month [6][8] Strategic Developments - Prenetics completed a $44 million equity offering in October 2025, attracting strategic investors, which positions the company for accelerated global expansion [3][10] - The company maintains a strong balance sheet with approximately $120 million in total liquidity and zero debt, allowing for aggressive scaling without dilutive capital needs [10][15] - Prenetics is executing a strategic review of non-core assets to focus on its highest-growth unit, IM8, following the successful divestiture of ACT Genomics [18][19] Market Positioning - IM8 is recognized for having the fastest growth trajectory in the global supplements industry, achieving $108 million in ARR within 11 months of launch [25][2] - The company is also pioneering a dual-engine strategy by integrating Bitcoin as a strategic treasury asset, currently holding 387 BTC valued at approximately $41 million [16][26] - Prenetics aims to replicate the success of direct-to-consumer brands like Hims & Hers, leveraging strong unit economics and a subscription-based revenue model [11][21]

Financial Performance - Company reported a revenue of $32.3 million for the first half of 2025, reflecting a year-over-year increase of 452.1% compared to the first half of 2024 [1][5] - In the second quarter of 2025, revenue reached $17.7 million, an increase of 594.9% compared to the second quarter of 2024 [5][30] - Gross profit for the first half of 2025 was $13.2 million, up 166.4% from the same period in 2024 [5] - Adjusted EBITDA loss for the first half of 2025 was $(8.7) million, which is an increase of 45.4% compared to the first half of 2024 [5] Business Unit Performance - IM8 generated $15.5 million in revenue for the first half of 2025, with a monthly revenue of $5.9 million in August 2025, indicating a CAGR of over 3,100% [6][12] - Europa and CircleDNA contributed $12.0 million and $4.8 million, respectively, to the first half revenue [13][36] - IM8's revenue in the second quarter was $9.8 million, a 70% increase over the first quarter of 2025 [5] Strategic Initiatives - Company has initiated a disciplined Bitcoin treasury strategy, acquiring a total of 228 Bitcoin as of September 10, 2025, with an unrealized gain of approximately $1.6 million [15][16] - Prenetics aims to achieve break-even by Q1 2026 and has increased its full-year 2025 revenue guidance to a range of $85 - $100 million [17][18] Market Position and Brand Development - IM8 has rapidly emerged as one of the fastest-growing supplement brands globally, with over 8 million servings delivered and more than 300,000 customer orders [10][12] - The brand's marketing efforts, including a partnership with Aryna Sabalenka, have significantly enhanced its visibility, generating 233 million views during the US Open [10][11] Financial Health - As of September 10, 2025, the company held $90 million in cash and Bitcoin, remaining debt-free [2][5] - Adjusted current assets were reported at $90.3 million, including $63.5 million in cash [5][38]

Core Insights - Prenetics Global Limited reported a significant revenue growth of 452.1% year-over-year, reaching $32.3 million in the first half of 2025 [1][5] - The company achieved a remarkable monthly revenue of $5.9 million in August 2025 for its IM8 brand, with a compound annual growth rate (CAGR) exceeding 3,100% [1][12] - Prenetics has increased its full-year 2025 revenue guidance to a range of $85 million to $100 million and anticipates reaching break-even by Q1 2026 [1][17] Financial Performance - In Q2 2025, Prenetics generated $17.7 million in revenue, marking a 594.9% increase compared to Q2 2024 [5] - The gross profit for Q2 2025 was $7.3 million, up 233.5% from the same quarter in the previous year [5] - The adjusted EBITDA loss for Q2 2025 was $(4.1) million, a decrease of 8.7% compared to Q1 2025 [5] - The total loss for Q2 2025 was $(10.9) million, reflecting a 22.7% increase from Q2 2024 [5] Business Unit Performance - IM8 generated $9.8 million in revenue for Q2 2025, a 70% increase over Q1 2025 [5] - Europa and CircleDNA contributed $5.7 million and $2.2 million in revenue, respectively, for Q2 2025 [5] - For the first half of 2025, IM8's revenue was $15.5 million, while Europa and CircleDNA generated $12.0 million and $4.8 million, respectively [13] Strategic Initiatives - Prenetics has initiated a disciplined Bitcoin treasury strategy, acquiring a total of 228 Bitcoin, with a daily accumulation of 1 BTC starting August 2025 [1][15] - The company holds a strong cash position of $90 million, including $26.1 million in Bitcoin, and remains debt-free [2][5] - Prenetics aims to enhance shareholder value through its strategic focus on both health and wealth optimization [2] Market Position and Growth Potential - IM8 has positioned itself as one of the fastest-growing supplement brands globally, with over 8 million servings delivered and more than 300,000 customer orders [12][10] - The brand's marketing efforts, including a partnership with Aryna Sabalenka, have significantly increased brand awareness, generating 233 million views during the US Open [10] - The company is optimistic about future product launches that will further solidify IM8's leadership in premium nutrition and longevity solutions [11]

Core Insights - Prenetics Global Limited announced a partnership between its premium supplements brand IM8 and world No. 1 tennis player Aryna Sabalenka, who becomes the brand's global ambassador and shareholder [1][6][12] - This partnership is significant as it marks the first endorsement of a supplement brand by Sabalenka, who has reported substantial benefits from using IM8's Daily Ultimate Essentials [3][4][5] Company Overview - Prenetics is a leading consumer health sciences company listed on NASDAQ under the ticker PRE, focusing on advancing consumer health through various initiatives, including IM8 [10] - IM8, co-founded by David Beckham, has rapidly grown to generate over US$50 million in Annual Recurring Revenue within just six months of its launch [6][8] - IM8 has built a loyal customer base of over 60,000 users, delivering more than 5 million servings of its products [6][8] Product Details - IM8's flagship product, Daily Ultimate Essentials, is designed to replace 16 different supplements with a single, NSF Certified for Sport® powder supplement [11] - The product is non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors, or sweeteners [11] Market Context - The partnership comes at a time when supplement safety and quality are critical issues in professional sports, with IM8's NSF Certified for Sport® designation ensuring rigorous testing for prohibited substances [7] - IM8's revenue growth trajectory exceeds typical benchmarks for successful supplement launches by 500%, indicating strong market demand and acceptance [8]

Core Insights - Prenetics Global Limited announced a partnership between its premium supplements brand IM8 and world No. 1 tennis player Aryna Sabalenka, who becomes the brand's global ambassador and shareholder [1][6][12] - This partnership is significant as it marks the first endorsement of a supplement brand by Sabalenka, who has reported substantial benefits from using IM8's Daily Ultimate Essentials [3][4][6] Company Overview - Prenetics is a leading consumer health sciences company listed on NASDAQ under the ticker PRE, focusing on advancing consumer health through innovative products [10] - IM8, co-founded by David Beckham, is a rapidly growing health and wellness brand that has achieved over US$50 million in Annual Recurring Revenue within six months of its launch [6][8][11] Product Details - IM8's flagship product, Daily Ultimate Essentials, is designed to replace 16 different supplements with a single, NSF Certified for Sport® powder supplement, ensuring safety and efficacy for athletes [11][12] - The product has gained a loyal customer base of over 60,000 users, who have consumed more than 5 million servings [6][8] Market Position - IM8 is recognized as one of the fastest-growing supplement brands globally, with its revenue velocity exceeding typical benchmarks for successful launches by 500% [8] - The partnership with Sabalenka comes at a time when supplement safety and quality are critical issues in professional sports, highlighting the importance of IM8's NSF certification [7][8] Athlete Endorsement - Aryna Sabalenka's personal experience with IM8 has led her to not only endorse the brand but also invest in it, reflecting her confidence in the product's quality and effectiveness [5][7] - The collaboration emphasizes the alignment of Sabalenka's values of athletic excellence and professionalism with IM8's commitment to quality and innovation [7][9]